WO2022144927A1 - A method of preparation of pure pharmaceutical compounds and pharmaceutical formulation thereof - Google Patents
A method of preparation of pure pharmaceutical compounds and pharmaceutical formulation thereof Download PDFInfo
- Publication number
- WO2022144927A1 WO2022144927A1 PCT/IN2021/051222 IN2021051222W WO2022144927A1 WO 2022144927 A1 WO2022144927 A1 WO 2022144927A1 IN 2021051222 W IN2021051222 W IN 2021051222W WO 2022144927 A1 WO2022144927 A1 WO 2022144927A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- usa
- degree
- soluble
- day
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 206010063094 Cerebral malaria Diseases 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 27
- 229940109262 curcumin Drugs 0.000 claims description 22
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 22
- 235000012754 curcumin Nutrition 0.000 claims description 20
- 239000004148 curcumin Substances 0.000 claims description 20
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims description 17
- 239000002105 nanoparticle Substances 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 14
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 13
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 13
- 229960004191 artemisinin Drugs 0.000 claims description 13
- 229930101531 artemisinin Natural products 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- 229940068968 polysorbate 80 Drugs 0.000 claims description 13
- 229940016667 resveratrol Drugs 0.000 claims description 13
- 235000021283 resveratrol Nutrition 0.000 claims description 13
- 239000002002 slurry Substances 0.000 claims description 13
- 239000012901 Milli-Q water Substances 0.000 claims description 11
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims description 10
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims description 10
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 10
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 10
- 235000002780 gingerol Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010014612 Encephalitis viral Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000002498 viral encephalitis Diseases 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 6
- 238000004108 freeze drying Methods 0.000 claims 6
- 238000005507 spraying Methods 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 201000004792 malaria Diseases 0.000 abstract description 7
- 239000003430 antimalarial agent Substances 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 4
- 230000003612 virological effect Effects 0.000 abstract description 4
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 3
- 230000000324 neuroprotective effect Effects 0.000 abstract description 3
- 230000003071 parasitic effect Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 52
- 210000003743 erythrocyte Anatomy 0.000 description 22
- 210000004556 brain Anatomy 0.000 description 19
- 238000011740 C57BL/6 mouse Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 208000030852 Parasitic disease Diseases 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 208000009182 Parasitemia Diseases 0.000 description 10
- 241000224021 Plasmodium berghei ANKA Species 0.000 description 10
- 230000008499 blood brain barrier function Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 210000001218 blood-brain barrier Anatomy 0.000 description 8
- 210000005013 brain tissue Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 244000045947 parasite Species 0.000 description 7
- 230000000770 proinflammatory effect Effects 0.000 description 7
- 101100260032 Mus musculus Tbx21 gene Proteins 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 230000000078 anti-malarial effect Effects 0.000 description 5
- 229960003699 evans blue Drugs 0.000 description 5
- 238000010212 intracellular staining Methods 0.000 description 5
- 206010015866 Extravasation Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 208000035999 Recurrence Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000036251 extravasation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- -1 allylated chalcone9 Chemical compound 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000003961 neuronal insult Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960004991 artesunate Drugs 0.000 description 2
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000011815 naïve C57Bl6 mouse Methods 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- TITLE A METHOD OF PREPARATION OF PURE PHARMACEUTICAL
- the present invention deals with a novel method of preparation of pharmaceutical compounds in highly pure, bioactive and bioavailable form and a novel pharmaceutical composition thereof comprising of strong antimalarial agents, followed by immunomodulatory and anti-inflammatory and neuroprotective compounds of the present invention used for the treatment diseases of parasitic or viral origin like malaria particularly cerebral malaria, Covid- 19, its variants etc. and its administration.
- Cerebral malaria is one of the major complications arising out of Plasmodium falciparum infection in humans. It is associated with severe disturbances of the consciousness (deep coma), respiratory distress and other neurological abnormalities.
- the pathogenesis of human cerebral malaria stems from a dys -regulated, hyper-inflammatory immune response that leads to the breach of the blood brain barrier and entry of parasitized erythrocytes and other toxic agents into the brain causing extensive neuronal damage.
- the World Health Organization has recommended intravenous administration of artesunate as the first line of treatment for severe malaria.
- artesunate and other artemisinin derivatives at high concentrations are toxic and despite their effectiveness, malaria results in 4,05,000 deaths each year all over the world and a significant percentage of individuals’ present neurological and memory deficits even after cure.
- Artemesinin is a very potent plant derived antimalarial. But it is not soluble in water and therefore has been derivatised and has to be injected. It controls parasitemia very rapidly but does not reduce inflammation and repair neuronal damage. Curcumin is an anti-inflammatory molecule and can prevent neuronal damage. Therefore a synergisticcombination therapy of Artemesin derivatives which has to be injected along with oral delivery of natural curcumin as such or after embedding onto PLGA nano particles to improve bioavailability has been used. This combination has made the animals to survive upto90 days. Nanotized curcumin holds a considerable promise in therapeutics as demonstrated in the work done till date for treating malaria as a test system.
- the present invention deals with a novel method of preparation of pharmaceutical compounds in highly pure, bioactive and bioavailable form and a novel pharmaceutical composition used for the treatment of diseases of parasitic or viral origin like malaria particularly cerebral malaria, Covid- 19, its variants and other viral infections, etc.
- Figure 1 FTIR profile of allylatedchalcone 9, soluble allylatedchalcone 9, andrographolide, soluble andrographolide, artemisinin, soluble artemisinin, resveratrol, soluble resveratrol, natural curcumin and soluble natural curcumin.
- FIG. 1 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 followed by intraperitoneal injection of 1X10 A 6 P berghei ANKAparasitised RBCs to mice belonging to G2 & G3 groups. Gl was left uninfected. G2 mice were treated with 200 ul of PBS orally from day 3 to day 10 post infection.
- G3 were treated with combinations A-F a) Survival data of Gl, G2 and G3 (Combinations A-F) groups b) Parasitemia data of Gl, G2 and G3 (Combination F) groups c) Differential staining of brain tissues from Gl, G2 and G3 (Combination F) groups with Evan’s Blue Dye on day 10-12 post infection. d) Quantitation of Evan’s Blue Dye extravasation into the brains of mice from Gl, G2 and G3 (Combination F) groups
- FIG. 3 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 (Combination F) as described in Figure 2.
- mRNA was isolated from the brains of mice belonging to Gl, G2 and G3 groups on day 10-12 post infection to compare the changes in the level of gene expresssion of a) IFN gamma, b) MIP 1 beta, c) IL 12, d) IL 1 beta, e) CCR7, f) CXCR3, g) CXCL10, h) ICAM 1, i) PD1, j) PDL1, k) PDL2, 1) CTLA4, m) CD40, o) CD80, p) CD86 in the brain. Data has been normalized to GAPDH and expressed as mean + S.D of relative fold change in mRNA expression and is representative of two independent experiments. [*P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, n.s: not significant].
- FIG. 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 (Combination F) as described in Figure 2. Serum was collected from mice belonging to Gl, G2 and G3 groups on day 10-12 post infection to measure the levels of a) IFN gamma, b) TNF alpha, c) IL 12, d) IL 6, e) IL 4 and f) IL 10
- Fig 5. 6-8 week old female C57BL/6 mice were infected with 1X1O A 6 P. berghei ANKA parasitised RBCs and divided into different groups Gl, G2, G3 (Combination F) as described in Figure 2. Spleens were collected on day 10-12 post infection from Gl, G2 and G3 groups.
- Splenocytes were isolated and surface stained with anti-mouse CD3 FITC conjugated antibodies and anti-mouse CD4 PB conjugated antibodies. Intracellular staining with Anti mouse Tbet APC conjugated antibodies was performed to determine the percentages of CD3+ CD4+ Tbet+ T cells in the spleen of Gl, G2 and G3 groups on day 10-12 post infection.
- Splenocytes were isolated and surface stained with anti-mouse CD3 FITC conjugated antibodies, anti mouse CD4 PB conjugated antibodies and anti mouse CD25_APC-Cy7 conjugated antibodies.
- Intracellular staining with Anti mouse FOXP 3_ Alexa Fluor® 647 conjugated antibodies was performed to determine the percentages of CD3+ CD4+ CD25+ FOXP 3+ T cells in the spleen of Gl, G2 and G3 groups on day 10-12 post infection.
- Fig. 6 TEM images of A) ART B) AC9 C) AND D) CUR E) GIN and F) RES showing spherical shaped nanoparticles. Scale bar 100 nm.
- Pdl polydispersity index
- the present invention relates to a method of manufacture of pure, bioactive and bioavailable water soluble forms of active ingredient(s) and a pharmaceutical formulations comprising of synergistic formulation ofstrongantimalarials to first reduce the parasite load in the blood, followed by the use of potent immunomodulators of natural origin to reduce inflammation, and finally used antiinflammatory and neuroprotective compounds that can prevent/repair the damage to the blood brain barrier and promote neuronal survival and development.
- the inventors of the present invention found that the compound Artemesinin and allylated chalcone9 are synergestic to each other and was givenorally at a specific stoichometric combination from the 3 rd day to 8 th day to P berghei ANKA infected mice for controlling parasitemia. Then a combination of plant derived compounds with immunomodulatory potential like andrgrapholide and gingerol (both of which also possess moderate antimalarial activities) has been given orallyfrom 5 th day till 8 lh day. Then a combination of NfKb inhibitors like curcumin which is anti-inflammatory andneuro protective, was given orally from 7 th day till 10 th day.As a result of this overlapping administration of the formulation for 10 daysthe animals controlled the parasite in the blood, reduced inflammation and protected the blood brain barrier.After 4weeks when the parasite specific 18srRNA appeared in the blood of the animal the administration of the pharmaceutical formulation was repeated again which kept the animals healthy till 120 days. After that the natural
- the inventors have developed water soluble forms of all the identified active compounds, namely artemisinin, allylated chalcone9, andrographolide, gingerol, resveratrol and curcumin that can be given orally for the treatment of a diseases to provide therapeutic efficacy.
- Artemisinin is a strong and fast acting antimalarial but is not water soluble in its natural state. Therefore the use of artemisinin as an antimalarial is mediated by making synthetic derivatives of artemisinin that makes it more water soluble and stable.
- Allylated chalcone9 is a water insoluble synthetic chaicone derivative that has mild antimalarialactivity and has been shown to be synergistic with artemisinin against chloroquine resistant strains of Plasmodium falciparum in vitro.
- andrographolide, gingerol, resveratrol and curcumin are all water insoluble in their natural occurrences, which greatly limits their therapeutic use.
- the present invention provides sufficient data to demonstrate and establishes that oral administration of water soluble artemisinin at Img/mice, and water soluble allylated chalcone9 at 2mg/mice to P.berghei ANKA infected mice for 6 days from 3 rd to 8 th day post infection followed by feeding of water soluble andrographolide and gingerol at Img/mice for 4 days from 5 th day till 8 th day post infection , which was followed by oral administration of water soluble forms of potent NFkB inhibitors like curcumin and resveratrol at 3mg/mice for 4 days from 7 th day till 10 th day post infection prevented cerebral malaria pathology, delayed recrudescence and prolonged survival of C57BL/6 mice infected with P. berghei ANKA.
- water solubility of insoluble pharmaceutical compounds has significantly been increased when manufactures by the method disclosed herein after.
- the pharmaceutical compounds thus prepared exhibit significantly increased bioavailability and efficacy.
- a pharmaceutical formulation prepared using the actives as prepared by aforementioned method and pharmaceutical acceptable excipients would be highly effective.
- the water soluble pharmaceutical compounds like Nanocurcumin (CUR), Nanoartemisinin (ART), Nano allylated chalcone9 (AC9) Nanoandrographolide (AND), Nanogingerol (GIN) and Nanoresveratrol (RES) were prepared according to the following procedure.
- a clear solution of 1-50 g of curcumin, or artemisinin, or gingerol, or resveratrol, or andrographolide, or allylatedchalcone 9or any other water insoluble pharmaceutical compound wasprepared by dissolving the compoundsindividually in 0.5-5 L of hot distilled ethanol.
- the solution was sprayed into equal volume ofMilliQ water containing 0.1-5.0 % polysorbate 80, and kept at 60 degree C and stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12, GOO- 15, 000 RPM over a period of 1 hour until the dissolved material precipitates.
- the precipitated material was filtered from the slurry and homogenized after suspending in 1 -5 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed.
- the suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain nanoparticles of 10-500 nm range which makes the compounds soluble in water.
- pharmaceutical formulations prepared are on the basis of the ability of the formulation to reduce inflammation and improve survivability without pathology generally associated with cerebral malaria infection, we prefer the formulation F in which (1 to 3 mg ART + 2 to 5 mg AC9) was given per mice orally in 200 pl PBS from day 3 post infection till day 8 post infection overlapped with a combination of (1 to 3 mg GIN + 0.5 to 3 mg AND) per mice from day 5 post infection till day 8 post infection and a combination of ( 1 to 3 mg RES + 3 to 5mg CUR) per mice from day 7 post infection till day 10 post infection.
- mice 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 followed by intraperitoneal injection of 1X10 A 6 P berghei ANKAparasitised RBCs to mice belonging to G2 & G3 groups. Gl was left uninfected. G2 mice were treated with 200 ul of PBS orally from day 3 to day 10 post infection. G3 were treated with the combinations A-F. The histological findings between the groups in comparison to uninfected (control) group in the spleen of mice (3 mice per group) were tabulated.
- + is used to denote the severity and extent of the parameters at the site according to the following scale:- 1+ means ⁇ 25 % RBCs are parasitized, 2+ means 25-50 % RBCs are parasitized, 3+ means 50-75 % RBCs are parasitized, 4+ means > 75 % RBCs are parasitized, Absent - 0% RBCs parasitized.
- mice 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 followed by intraperitoneal injection of 1X10 A 6 P berghei ANKAparasitised RBCs to mice belonging to G2 & G3 groups. Gl was left uninfected. G2 mice were treated with 200 ul of PBS orally from day 3 to day 10 post infection. G3 were treated with the combinations A-F. The histological findings between the groups in comparison to uninfected (control) group in the brain of mice (3 mice per group) were tabulated.
- + is useto denote the severity and extent of the parameters at the site according to the following scale:- 1+ means ⁇ 25 % RBCs are parasitized, + means 25-50 % RBCs are parasitized, 3+ means 50-75 % RBCs are parasitized, 4+ means > 5 % RBCs are parasitized, Absent - 0% RBCs parasitized.
- the formulations would be highly effective in the treatment of Uncomplicated and complicated malaria including Cerebral Malaria, and MA-ARDS, Severe COVID 19, Viral encephalitis, Inflammatory bowel disease and other inflammatory responses as a result of any other diseases.
- Example 1 Experimental Cerebral Malaria model and drug administration
- P. berghei ANKA was revived from cryopreserved samples and maintained in 6-8 weeks old female C57BL/6 mice, weighing 18-20 g (de Oca et al., 2013). Blood was collected from infected donor C57BL/6 mice at parasitemia>l% and IxlO 6 parasitized RBCs (pRBCs) were passaged rapidly into naive C57BL/6 mice every fourth to fifth day by i.p injection.
- mice are euthanized by carbon dioxide asphyxiation and 500 pl (optimal) blood is collected by cardiac puncture and transferred to 4.5 ml of RPMI/PS media (RPMI+1% PenStrep) containing 5 pl heparin (5,000 lU/ml) in a 10 ml polypropylene tube.
- the volume was then made upto 10 ml by adding 5 ml of RPMI/PS media.
- the cells were then centrifuged at 1,127 x g for 7 minutes at room temperature. The supernatant was then carefully aspirated and the pellet was resuspended in 1 ml RPMI/PS media.
- mice 6-8 week old female C57BL/6 mice were randomly divided into 3 groups (G1-G3) followed by infection of lxlO 6 P. berghei ANKA parasitized RBCs by i.p injection into each mice from Groups G2 and G3.
- Group 1 (Gl) mice served as the uninfected normal control.
- the mice belonging to Group G2 were given 200 ul PBS per mice orally from day 3 to day 10 post infection and served as the infected untreated control.
- the formulation F in which ( 1 to 3 mg ART + 2 to 5 mg AC9) was given per mice orally in 200 pl PBS from day 3 post infection till day 8 post infection overlapped with a combination of (1 to 3 mg GIN + 0.5 to 3 mg AND) per mice from day 5 post infection till day 8 post infection and a combination of ( 1 to 3 mg RES + 3 to 5mg CUR) per mice from day 7 post infection till day 10 post infection.
- curcumin (Sigma, USA) were dissolved in 0.8-1 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 0.5- 3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol concentration became 50-40% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM.
- a high-speed homogenizer T 25 digital ULTRA-TURAX, IKA, USA
- the precipitated material was filtered from the slurry and homogenized after suspending in 1-2 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed.
- the suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain curcumin nanoparticles (CUR) of 10-500 nm range which makes the compounds soluble in water.
- CUR curcumin nanoparticles
- Example 4 Preparation of soluble gingerol 1-5 grams of gingerol (Sigma, USA) were dissolved in 3-5 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 1- 3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol concentration became 60-50% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM.
- a high-speed homogenizer T 25 digital ULTRA-TURAX, IKA, USA
- the precipitated material was filtered from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed.
- the suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain gingerolnanoparticles (GIN) of 10-500 nm range which makes the compounds soluble in water.
- GIN gingerolnanoparticles
- the precipitated material was filtered from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly dispersed.
- the suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain resveratrol nanoparticles (RES) of 10-500 nm range which makes the compounds soluble in water.
- RES resveratrol nanoparticles
- the precipitated material was filtered from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed.
- the suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain curcumin nanoparticles (CUR) of 10-500 nm range which makes the compounds soluble in water.
- CUR curcumin nanoparticles
- Allylatedchalcone9 was first synthesized in accordance to published literature (Sharma et al., 2014).
- curcumin (Sigma, USA) were dissolved in 1-3 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 0.5- 3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol concentration became 40-50% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM.
- a high-speed homogenizer T 25 digital ULTRA-TURAX, IKA, USA
- the precipitated material was filtered from the slurry and homogenized after suspending in 1-2 L of MilliQ water in an ultrasonic probe sonicatorat 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed.
- the suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain allylatedchalconenanoparticles (AC9) of 10-500 nm range which makes the compounds soluble in water.
- Blood parasitemia was determined from smears prepared from tail blood followed by fixation in absolute methanol for 1 minute, Acridine Orange staining and observation in a fluorescent microscope under 60X magnification . Percentage parasitemia in the blood was calculated according to the formula:
- Example 9 Blood Brain Barrier permeability
- Example 11 Serum cytokine Analysis by ELISA
- Cytokine levels were measured in serum samples collected on day 10-12 post infection from mice from Groups G1-G3, using DuoSet mouse ELISA kits (R&D systems) as per the manufacturer’s protocol. Biotinylated Detection Antibody and Avidin-HRP conjugate were used with TMB liquid substrate to give a colored product. Reaction was stopped using 2N H2SO4 and absorbance at 450 nm was measured to detect and quantify the levels of IFN gamma, TNF alpha, IL 12, IL 6, IL 4 and IL 10 in the serum.
- Example 12 FACS analysis of splenocytes
- Spleens were collected on day 10-12 post infection from the Groups G1-G3. Splenocytes were isolated from the spleen and subjected to erythrocyte lysis and blocked with blocking buffer (30% FBS in PBS) for 30 minutes at 4 degree C. The cells were then washed with 2 ml PBS, counted and split into respective tubes keeping the count to IX 10 6 cells per tube. Surface staining for each sample from each group was done with a cocktail of anti mouse CD3-FITC conjugated antibodies and anti mouse CD4-PB conjugated antibodies. For Treg set, the samples were additionally stained with anti mouse CD25-APC-Cy7 conjugated antibodies.
- the samples were then permeabilized and intracellular staining for the different sets was done using anti mouse Tbet-APC conjugated antibodies, anti mouse GATA3-APC conjugated antibodies, and anti mouse FoxP3-APC conjugated antibodies respectively.
- intracellular staining the cells were fixed with 1% paraformaldehyde and stored in dark at 4 degree C. FACS analysis was done in FACS Canto II machine.
- Example 15 Blood Brain Barrier permeability
- berghei ANKA infected mice with combination therapy F significantly decreased the expression of IFN gamma (Fig 3a), MIP 1 beta (Fig 3b), IL 12 (Fig 3c), IL 1 beta (Fig 3d), CCR7 (Fig 3e), CXCR3 (Fig 3f), CXCL10 (Fig 3g), ICAM 1 (Fig 3h), PD1 (Fig 3i), PDL1 (Fig 3j), PDL2 (Fig 3k), CTLA4 (Fig 31), CD40 (Fig 3m) , CD80 (Fig 3o), CD86 (Fig 3p), in the brain.
- Example 17 Serum cytokine Analysis by ELISA
- the mean levels of IFN gamma (Fig 4a), TNF alpha (Fig 4b), IL 12 (Fig 4c), IL 6 (Fig 4d), IL 4 (Fig 4e) and IL 10 (Fig 4f) in the serum of uninfected (Gl) mice were 71.5, 39.5, 91.0, 28.5, 11.5 and 79.0 pg/ml respectively.
- mice The mean levels of IFN gamma (Fig 4a), TNF alpha (Fig 4b), IL 12 (Fig 4c), IL 6 (Fig 4d), IL 4 (Fig 4e) and IL 10 (Fig 4f) in the serum of untreated (G2) mice were 1180.0, 474.5, 1118.5, 487.5, 27.0 and 260.5 pg/ml respectively.
- mice The mean levels of IFN gamma (Fig 4a), TNF alpha (Fig 4b), IL 12 (Fig 4c), IL 6 (Fig 4d), IL 4 (Fig 4e) and IL 10 (Fig 4f) in the serum of Combination treated (G3, Combination F) mice were 110.5, 41.0, 124.5, 28.5, 39.5 and 189.5 pg/ml respectively. Infection with P. berghei ANKA resulted in significant increase of the pro inflammatory cytokines IFN gamma, TNF alpha, IL 12, and IL 6 in the blood.
- Example 18 FACS analysis of splenocytes
- Flow cytometric analysis indicated a change in the Thl/Th2 axis of infected untreated animals (G2) on day 10-12 post infection in comparison to uninfected animals (Gl) with the response in the case of infected untreated animals being more Thl skewed as evidenced by a increased expression of Tbet and lowered expression of GATA3 in CD3 + CD4 + T cells isolated from the spleen (Fig. 5B).
- the expression of CD3+CD4+CD25+Foxp3 T cells (Fig. 5c) in the spleen of infected untreated (G2) animals on day 10-12 post infection was 5.0% in comparison to 8.9% in the uninfected animals (Gl).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention deals with a novel method of preparation of pharmaceutical compounds in highly pure, bioactive and bioavailable form and a novel pharmaceutical composition thereof comprising of strong antimalarial agents, followed by immunomodulatory and anti-inflammatory and neuroprotective compounds of the present invention used for the treatment diseases of parasitic or viral origin like malaria particularly cerebral malaria, Covid-19, its variants etc. and its administration.
Description
TITLE: A METHOD OF PREPARATION OF PURE PHARMACEUTICAL
COMPOUNDS AND PHARMACEUTICAL FORMULATION THEREOF
FIELD OF THE INVENTION:
The present invention deals with a novel method of preparation of pharmaceutical compounds in highly pure, bioactive and bioavailable form anda novel pharmaceutical composition thereof comprising of strong antimalarial agents, followed by immunomodulatory and anti-inflammatory and neuroprotective compounds of the present invention used for the treatment diseases of parasitic or viral origin like malaria particularly cerebral malaria, Covid- 19, its variants etc. and its administration.
BACKGROUND OF THE INVENTION:
Cerebral malaria (CM) is one of the major complications arising out of Plasmodium falciparum infection in humans. It is associated with severe disturbances of the consciousness (deep coma), respiratory distress and other neurological abnormalities. The pathogenesis of human cerebral malaria stems from a dys -regulated, hyper-inflammatory immune response that leads to the breach of the blood brain barrier and entry of parasitized erythrocytes and other toxic agents into the brain causing extensive neuronal damage.
The World Health Organization (WHO) has recommended intravenous administration of artesunate as the first line of treatment for severe malaria. However, artesunate and other artemisinin derivatives at high concentrations are toxic and despite their effectiveness, malaria results in 4,05,000 deaths each year all over the world and a significant percentage of individuals’ present neurological and memory deficits even after cure.
Because of the difficulty in observing the cellular mechanisms associated with cerebral malaria directly in the human brain, it is imperative to use an animal model that closely reflects the clinical symptoms, immune mechanisms and histopathology associated with human cerebral malaria. P. berg he i ANKA infected CBA, Swiss Webster, or CB57B1/6 mice represent a model that is well- characterized and widely used for studying experimental cerebral malaria (ECM) that shares several similarities with P. falciparum induced cerebral malaria in humans. Both ECM and human
cerebral malaria are characterized by severe vasculopathy, i.e. endothelial activation and dysfunction with increased expression of adhesion molecules, upregulation of pro inflammatory cytokines, reduced blood flow, vascular leakage, acute edema of both vasogenic and cytotoxic origin, and microhemorrhages leading to neurological impairment.
Artemesinin is a very potent plant derived antimalarial. But it is not soluble in water and therefore has been derivatised and has to be injected. It controls parasitemia very rapidly but does not reduce inflammation and repair neuronal damage. Curcumin is an anti-inflammatory molecule and can prevent neuronal damage. Therefore a synergisticcombination therapy of Artemesin derivatives which has to be injected along with oral delivery of natural curcumin as such or after embedding onto PLGA nano particles to improve bioavailability has been used. This combination has made the animals to survive upto90 days. Nanotized curcumin holds a considerable promise in therapeutics as demonstrated in the work done till date for treating malaria as a test system.
There exist a demand for an improved formulation for the treatment of cerebral malaria, other parasitic diseases, viral diseases and other diseases those can be treated by the identified actives and a huge scope for the improvement to utilize these actives to their full potential.
SUMMARY OF THE INVENTION
The present invention deals with a novel method of preparation of pharmaceutical compounds in highly pure, bioactive and bioavailable form and a novel pharmaceutical composition used for the treatment of diseases of parasitic or viral origin like malaria particularly cerebral malaria, Covid- 19, its variants and other viral infections, etc.
BRIEF DESCRIPTION OF THE DRAWINGS
1. Figure 1. FTIR profile of allylatedchalcone 9, soluble allylatedchalcone 9, andrographolide, soluble andrographolide, artemisinin, soluble artemisinin, resveratrol, soluble resveratrol, natural curcumin and soluble natural curcumin.
2. Figure 2. 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 followed by intraperitoneal injection of 1X10A6 P berghei ANKAparasitised RBCs to mice belonging to G2 & G3 groups. Gl was left uninfected. G2 mice were treated with 200 ul of PBS orally from day 3 to day 10 post infection. G3 were treated with combinations A-F
a) Survival data of Gl, G2 and G3 (Combinations A-F) groups b) Parasitemia data of Gl, G2 and G3 (Combination F) groups c) Differential staining of brain tissues from Gl, G2 and G3 (Combination F) groups with Evan’s Blue Dye on day 10-12 post infection. d) Quantitation of Evan’s Blue Dye extravasation into the brains of mice from Gl, G2 and G3 (Combination F) groups
Data is expressed as mean +_SD and is representative of three independent experiments.
3. Figure 3. 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 (Combination F) as described in Figure 2. mRNAwas isolated from the brains of mice belonging to Gl, G2 and G3 groups on day 10-12 post infection to compare the changes in the level of gene expresssion of a) IFN gamma, b) MIP 1 beta, c) IL 12, d) IL 1 beta, e) CCR7, f) CXCR3, g) CXCL10, h) ICAM 1, i) PD1, j) PDL1, k) PDL2, 1) CTLA4, m) CD40, o) CD80, p) CD86 in the brain. Data has been normalized to GAPDH and expressed as mean + S.D of relative fold change in mRNA expression and is representative of two independent experiments. [*P<0.05, **P<0.01, ***P<0.001, n.s: not significant].
4. Figure 4. 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 (Combination F) as described in Figure 2. Serum was collected from mice belonging to Gl, G2 and G3 groups on day 10-12 post infection to measure the levels of a) IFN gamma, b) TNF alpha, c) IL 12, d) IL 6, e) IL 4 and f) IL 10
Data is expressed as mean + S.D and is representative of two independent experiments. [*P<0.05, **P<0.01, ***P<0.001, n.s: not significant].
5. Fig 5. 6-8 week old female C57BL/6 mice were infected with 1X1OA6 P. berghei ANKA parasitised RBCs and divided into different groups Gl, G2, G3 (Combination F) as described in Figure 2. Spleens were collected on day 10-12 post infection from Gl, G2 and G3 groups.
A) Splenocytes were isolated and surface stained with anti-mouse CD3 FITC conjugated antibodies and anti-mouse CD4 PB conjugated antibodies.
Intracellular staining with Anti mouse Tbet APC conjugated antibodies was performed to determine the percentages of CD3+ CD4+ Tbet+ T cells in the spleen of Gl, G2 and G3 groups on day 10-12 post infection.
B) Splenocytes were isolated and surface stained with anti-mouse CD3 FITC conjugated antibodies and anti-mouse CD4 PB conjugated antibodies. Intracellular staining with Anti mouse GATA3 APC conjugated antibodies was performed to determine the percentages of CD3+ CD4+ GATA 3+ T cells in the spleen of Gl, G2 and G3 groups on day 10-12 post infection
C) Splenocytes were isolated and surface stained with anti-mouse CD3 FITC conjugated antibodies, anti mouse CD4 PB conjugated antibodies and anti mouse CD25_APC-Cy7 conjugated antibodies. Intracellular staining with Anti mouse FOXP 3_ Alexa Fluor® 647 conjugated antibodies was performed to determine the percentages of CD3+ CD4+ CD25+ FOXP 3+ T cells in the spleen of Gl, G2 and G3 groups on day 10-12 post infection.
Fig. 6 TEM images of A) ART B) AC9 C) AND D) CUR E) GIN and F) RES showing spherical shaped nanoparticles. Scale bar 100 nm. DLS profiles of ART, AC9, AND, CUR, GIN, and RES showing (hydrodynamic radius) of G) ART, H) AC9, 1) AND, J) CUR K) GIN and L) RES determined to be 327 ± 180.7 nm, 331 ± 221.9 nm, 335.2 ± 215.8 nm, 230.5 ± 137.7 nm, 315.6 ± 223.2 nm and 287.2 ± 209.6 respectively; with a polydispersity index (Pdl) of 0.197, 0.219, 0.227, 0.180, 0.446 and 0.244 respectively by dynamic light scattering analysis.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method of manufacture of pure, bioactive and bioavailable water soluble forms of active ingredient(s) and a pharmaceutical formulations comprising of synergistic formulation ofstrongantimalarials to first reduce the parasite load in the blood, followed by the use of potent immunomodulators of natural origin to reduce inflammation, and finally used antiinflammatory and neuroprotective compounds that can prevent/repair the damage to the blood brain barrier and promote neuronal survival and development.
The inventors of the present invention found that the compound Artemesinin and allylated chalcone9 are synergestic to each other and was givenorally at a specific stoichometric combination from the 3rdday to 8th day to P berghei ANKA infected mice for controlling parasitemia.Then a combination of plant derived compounds with immunomodulatory potential like andrgrapholide and gingerol (both of which also possess moderate antimalarial activities) has been given orallyfrom 5th day till 8lhday.Then a combination of NfKb inhibitors like curcumin which is anti-inflammatory andneuro protective, was given orally from 7th day till 10th day.As a result of this overlapping administration of the formulation for 10 daysthe animals controlled the parasite in the blood, reduced inflammation and protected the blood brain barrier.After 4weeks when the parasite specific 18srRNA appeared in the blood of the animal the administration of the pharmaceutical formulation was repeated again which kept the animals healthy till 120 days. After that the natural immune response took care of the parasite recrudescence.
The inventors have developed water soluble forms of all the identified active compounds, namely artemisinin, allylated chalcone9, andrographolide, gingerol, resveratrol and curcumin that can be given orally for the treatment of a diseases to provide therapeutic efficacy. Artemisinin is a strong and fast acting antimalarial but is not water soluble in its natural state. Therefore the use of artemisinin as an antimalarial is mediated by making synthetic derivatives of artemisinin that makes it more water soluble and stable. Allylated chalcone9 is a water insoluble synthetic chaicone derivative that has mild antimalarialactivity and has been shown to be synergistic with artemisinin against chloroquine resistant strains of Plasmodium falciparum in vitro. Likewise, andrographolide, gingerol, resveratrol and curcumin are all water insoluble in their natural occurrences, which greatly limits their therapeutic use. By converting these compounds into water soluble forms, without the need for derivatizing them and altering them chemically or embedding them into synthetic polymeric nanoparticles for enhancing their water solubility, the inventors utilized their inherent biological properties and combine them in a defined ratio used for the treatment of a disease in order to maximize the therapeutic efficacy againstcomplicated diseases like cerebral malaria, flu including flu caused by Covid- 19. The compounds prepared by method disclosed in the present invention would be significantly be more effective for treating all the disorders for which they are already known to have therapeutic effect.
The present invention provides sufficient data to demonstrate and establishes that oral administration of water soluble artemisinin at Img/mice, and water soluble allylated chalcone9 at 2mg/mice to P.berghei ANKA infected mice for 6 days from 3rd to 8th day post infection followed by feeding of water soluble andrographolide and gingerol at Img/mice for 4 days from 5th day till 8th day post infection , which was followed by oral administration of water soluble forms of potent NFkB inhibitors like curcumin and resveratrol at 3mg/mice for 4 days from 7th day till 10th day post infection prevented cerebral malaria pathology, delayed recrudescence and prolonged survival of C57BL/6 mice infected with P. berghei ANKA.
As an embodiment of the present invention water solubility of insoluble pharmaceutical compounds has significantly been increased when manufactures by the method disclosed herein after. The pharmaceutical compounds thus prepared exhibit significantly increased bioavailability and efficacy. Thus a pharmaceutical formulation prepared using the actives as prepared by aforementioned method and pharmaceutical acceptable excipients would be highly effective. The water soluble pharmaceutical compounds like Nanocurcumin (CUR), Nanoartemisinin (ART), Nano allylated chalcone9 (AC9) Nanoandrographolide (AND), Nanogingerol (GIN) and Nanoresveratrol (RES) were prepared according to the following procedure. Briefly, a clear solution of 1-50 g of curcumin, or artemisinin, or gingerol, or resveratrol, or andrographolide, or allylatedchalcone 9or any other water insoluble pharmaceutical compound wasprepared by dissolving the compoundsindividually in 0.5-5 L of hot distilled ethanol.The solution was sprayed into equal volume ofMilliQ water containing 0.1-5.0 % polysorbate 80, and kept at 60 degree C and stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12, GOO- 15, 000 RPM over a period of 1 hour until the dissolved material precipitates. The precipitated material was filtered from the slurry and homogenized after suspending in 1 -5 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed. The suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain nanoparticles of 10-500 nm range which makes the compounds soluble in water.
As yet another embodiment of the present invention, pharmaceutical formulations prepared are on the basis of the ability of the formulation to reduce inflammation and improve survivability without
pathology generally associated with cerebral malaria infection, we prefer the formulation F in which (1 to 3 mg ART + 2 to 5 mg AC9) was given per mice orally in 200 pl PBS from day 3 post infection till day 8 post infection overlapped with a combination of (1 to 3 mg GIN + 0.5 to 3 mg AND) per mice from day 5 post infection till day 8 post infection and a combination of ( 1 to 3 mg RES + 3 to 5mg CUR) per mice from day 7 post infection till day 10 post infection.
The enhanced effect achieved on the brain tissues by the administration of pharmaceutical composition of the present invention has been discussed in tables 1 and 2:
Table 1. 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 followed by intraperitoneal injection of 1X10A6 P berghei ANKAparasitised RBCs to mice belonging to G2 & G3 groups. Gl was left uninfected. G2 mice were treated with 200 ul of PBS orally from day 3 to day 10 post infection. G3 were treated with the combinations A-F. The histological findings between the groups in comparison to uninfected (control) group in the spleen of mice (3 mice per group) were tabulated. + is used to denote the severity and extent of the parameters at the site according to the following scale:- 1+ means < 25 % RBCs are parasitized, 2+ means 25-50 % RBCs are parasitized, 3+ means 50-75 % RBCs are parasitized, 4+ means > 75 % RBCs are parasitized, Absent - 0% RBCs parasitized.
Table 2. 6-8 week old female C57BL/6 mice were divided into different groups Gl, G2, G3 followed by intraperitoneal injection of 1X10A6 P berghei ANKAparasitised RBCs to mice belonging to G2 & G3 groups. Gl was left uninfected. G2 mice were treated with 200 ul of PBS orally from day 3 to day 10 post infection. G3 were treated with the combinations A-F. The histological findings between the groups in comparison to uninfected (control) group in the brain of mice (3 mice per group) were tabulated. + is useto denote the severity and extent of the parameters at the site according to the following scale:- 1+ means < 25 % RBCs are parasitized,
+ means 25-50 % RBCs are parasitized, 3+ means 50-75 % RBCs are parasitized, 4+ means > 5 % RBCs are parasitized, Absent - 0% RBCs parasitized.
Furthermore, the formulations would be highly effective in the treatment of Uncomplicated and complicated malaria including Cerebral Malaria, and MA-ARDS, Severe COVID 19, Viral encephalitis, Inflammatory bowel disease and other inflammatory responses as a result of any other diseases.
EXAMPLES:
The present invention is further being explained by the way of representative working examples. The scope of the invention is not limited to the working examples.
Example 1: Experimental Cerebral Malaria model and drug administration
P. berghei ANKA was revived from cryopreserved samples and maintained in 6-8 weeks old female C57BL/6 mice, weighing 18-20 g (de Oca et al., 2013). Blood was collected from infected donor C57BL/6 mice at parasitemia>l% and IxlO6 parasitized RBCs (pRBCs) were passaged rapidly into naive C57BL/6 mice every fourth to fifth day by i.p injection. Briefly, mice are euthanized by carbon dioxide asphyxiation and 500 pl (optimal) blood is collected by cardiac puncture and transferred to 4.5 ml of RPMI/PS media (RPMI+1% PenStrep) containing 5 pl heparin (5,000 lU/ml) in a 10 ml polypropylene tube. The volume was then made upto 10 ml by adding 5 ml of RPMI/PS media. The cells were then centrifuged at 1,127 x g for 7 minutes at room temperature. The supernatant was then carefully aspirated and the pellet was resuspended in 1 ml RPMI/PS media. An accurate count of parasitized RBC (pRBC) in the suspension was then made using a hemocytometer and an inoculum of 1X106 parasite infected RBCs, per 200 pl of RPMI/PS media was intraperitoneally injected into desired number of naive mice (de Oca et al., 2013). After 3 times passage in donor C57BL/6 mice, 1X1O6P. berghei ANKA parasites were intraperitoneally injected into experimental C57BL/6 mice as described, for the induction of ECM(100%) in infected mice.
To determine the efficacy of the specified combination regimen, 6-8 week old female C57BL/6 mice were randomly divided into 3 groups (G1-G3) followed by infection of lxlO6P. berghei
ANKA parasitized RBCs by i.p injection into each mice from Groups G2 and G3. Group 1 (Gl) mice served as the uninfected normal control. The mice belonging to Group G2 were given 200 ul PBS per mice orally from day 3 to day 10 post infection and served as the infected untreated control.
The experimental animals from Group G3 were treated with any of the following combination regimens
A) (0.5 to 2 mg ART + 1 to 3 mg AC9 + 0.5 to 2 mg AND + 1 to 3 mg CUR) per mice orally in 200 pl PBS from day 6 post infection till day 12 post infection
B) (0.5 to 2 mg ART + 1 to 3 mg AC9 + 0.5 to 2 mg AND + 1 to 3 mg CUR) per mice orally in 200 pl PBS from day 6 post infection till day 9 post infection and again from day 24 post infection to day 27 post infection.
C) (1 to 3 mg AC9 + 3 to 5 mg CUR) per mice orally in 200 pl PBS, twice daily from day 6 post infection till day 9 post infection
D) (0.5 to 3 mg ART + 1 to 3 mg CUR +0.5 to 1 mg GIN) per mice orally in 200 pl PBS, twice daily, from day 3 post infection till day 8 post infection
E) (1 to 3 mg ART + 2 to 5 mg RES) per mice orally in 200 pl PBS overlapped with a combination of (2 to 5 mg AC9 +1 to 3 mg CUR) at 6 hour intervals from day 6 post infection till day 9 post infection
F) (1 to 3 mg ART + 2 to 5 mg AC9) per mice orally in 200 pl PBS from day 3 post infection till day 8 post infection overlapped with a combination of (1 to 3 mg GIN + 0.5 to 3 mg AND) per mice orally in 200 pl PBS from day 5 post infection till day 8 post infection and a combination of (1 to 3 mg RES + 3 to 5mg CUR) per mice orally in 200 pl PBS from day 7 post infection till day 10 post infection
Preferred pharmaceutical forma latioa
On the basis of the ability of the formulation to reduce inflammation and improve survivability without pathology generally associated with cerebral malaria infection, we prefer the formulation F in which ( 1 to 3 mg ART + 2 to 5 mg AC9) was given per mice
orally in 200 pl PBS from day 3 post infection till day 8 post infection overlapped with a combination of (1 to 3 mg GIN + 0.5 to 3 mg AND) per mice from day 5 post infection till day 8 post infection and a combination of ( 1 to 3 mg RES + 3 to 5mg CUR) per mice from day 7 post infection till day 10 post infection.
Example 2: Preparation of soluble curcumin
1-10 grams of curcumin (Sigma, USA) were dissolved in 0.8-1 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 0.5- 3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol concentration became 50-40% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. The precipitated material was filtered from the slurry and homogenized after suspending in 1-2 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed. The suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain curcumin nanoparticles (CUR) of 10-500 nm range which makes the compounds soluble in water.
Example 3: Preparation of soluble artemisinin
10-20 grams of artemisinin (Sigma, USA) were dissolved in 1-2 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 1-3% polysorbate 80 over a period of 45 min to 1 hour until the ethanol concentration became 20-30% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. The precipitated material was filtered from the slurry and homogenized after suspending in 2-5 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed. The suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain artemisinin nanoparticles (ART) of 10-500 nm range which makes the compounds soluble in water.
Example 4: Preparation of soluble gingerol
1-5 grams of gingerol (Sigma, USA) were dissolved in 3-5 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 1- 3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol concentration became 60-50% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. The precipitated material was filtered from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed. The suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain gingerolnanoparticles (GIN) of 10-500 nm range which makes the compounds soluble in water.
Example 5: Preparation of soluble resveratrol
20-30 grams of resveratrol (Sigma, USA) were dissolved in 1-3 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 1-3% polysorbate 80 over a period of 30 min to 45 mins until the ethanol concentration became 20-30% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. The precipitated material was filtered from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly dispersed. The suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain resveratrol nanoparticles (RES) of 10-500 nm range which makes the compounds soluble in water.
Example 6: Preparation of soluble andrographolide
1-5 grams of Andrographolide (Sigma, USA) was dissolved in 0.5-1 L of a mixture of distilled ethanol and acetone in 9: 1 - 7:3 ratio at room temperature and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 2-3%
polysorbate 80 over a period of 30 min to 1 hour until the ethanol: acetone concentration became 60-50% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. The precipitated material was filtered from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed. The suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain curcumin nanoparticles (CUR) of 10-500 nm range which makes the compounds soluble in water.
Example 7: Preparation of soluble allylatedchalcone 9
Allylatedchalcone9 was first synthesized in accordance to published literature (Sharma et al., 2014).
1-5 grams of curcumin (Sigma, USA) were dissolved in 1-3 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. This solution was then slowly sprayed over a required volume of Milli Q water containing 0.5- 3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol concentration became 40-50% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. The precipitated material was filtered from the slurry and homogenized after suspending in 1-2 L of MilliQ water in an ultrasonic probe sonicatorat 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed. The suspension was then lyophilized at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain allylatedchalconenanoparticles (AC9) of 10-500 nm range which makes the compounds soluble in water.
Example 8: Parasitemia and survivability
Blood parasitemia was determined from smears prepared from tail blood followed by fixation in absolute methanol for 1 minute, Acridine Orange staining and observation in a fluorescent microscope under 60X magnification . Percentage parasitemia in the blood was calculated according to the formula:
[(Number of infected erythrocytes) / (Total number of erythrocytes) X 100%].
The mice were daily monitored for determining the period of survival.
Example 9: Blood Brain Barrier permeability
Blood Brain Barrier permeability was checked by Evan’s Blue Dye extravasations. On day 10-12 post infection, all experimental mice were anesthetized and given intravenous injection with 0.2% Evans Blue Dye (Sigma, St Louis, MO) in PBS and the dye was extracted from brain tissue after 2 hours in 100% formamide and the absorbance was measured at 620 nm to determine the extent of extravasations .
Example 10: Quantitative real time PCR analysis
Brains were harvested from mice from G1-G3 on day 10-12 post infection. RNA was extracted from brain samples using TRI reagent and 1 pg of RNA was taken for reverse transription reaction using random hexamers. The prepared cDNA was diluted 1 :20 times and used for qPCR in Applied Biosystems Step One Plus Real Time PCR System. GAPDH was kept as the endogenous control and relative fold expression was calculated by 2-AACT method.
Example 11: Serum cytokine Analysis by ELISA
Cytokine levels were measured in serum samples collected on day 10-12 post infection from mice from Groups G1-G3, using DuoSet mouse ELISA kits (R&D systems) as per the manufacturer’s protocol. Biotinylated Detection Antibody and Avidin-HRP conjugate were used with TMB liquid substrate to give a colored product. Reaction was stopped using 2N H2SO4 and absorbance at 450 nm was measured to detect and quantify the levels of IFN gamma, TNF alpha, IL 12, IL 6, IL 4 and IL 10 in the serum.
Example 12: FACS analysis of splenocytes
Spleens were collected on day 10-12 post infection from the Groups G1-G3. Splenocytes were isolated from the spleen and subjected to erythrocyte lysis and blocked with blocking buffer (30% FBS in PBS) for 30 minutes at 4 degree C. The cells were then washed with 2 ml PBS, counted and split into respective tubes keeping the count to IX 106 cells per tube. Surface staining for each sample from each group was done with a cocktail of anti mouse CD3-FITC conjugated antibodies and anti mouse CD4-PB conjugated antibodies. For Treg set, the samples were additionally stained with anti mouse CD25-APC-Cy7 conjugated antibodies. Following surface staining, the samples
were then permeabilized and intracellular staining for the different sets was done using anti mouse Tbet-APC conjugated antibodies, anti mouse GATA3-APC conjugated antibodies, and anti mouse FoxP3-APC conjugated antibodies respectively. Following intracellular staining, the cells were fixed with 1% paraformaldehyde and stored in dark at 4 degree C. FACS analysis was done in FACS Canto II machine.
Bioactivity analysis:
Example 13: Characterization of prepared compounds
The similarity ofartemesinin, allylatedchalcone 9, andrographolide, gingerol, resveratrol and natural curcumin with their corresponding soluble forms as determined by their bioactivity and FTIR spectra demonstrate that the soluble forms of the prepared compounds are unaltered in their chemical structure (Fig 1).
Example 14: Parasitemia and survivability
C57BL/6 mice that were infected with P. berghei ANKA and left untreated (G2) manifested neurological symptoms like ataxia, labored breathing, convulsions, hind leg paralysis and coma that ultimately resulted in death. The median survival period was 10 days and the average parasitemia at the time of death was 20 % (Fig 2a, 2b). Mice receiving combination treatment (G3, Combination F) did not develop any neurological symptoms and remained devoid of parasites till day 28 around when recrudescence was observed. A second dose at this time controlled the parasitemia completely and prevented further recrudescence (Fig 2b). All the treated animals went on to survive for 120 days, after which observation was discontinued (Fig 2a).
Example 15: Blood Brain Barrier permeability
One of the characteristic features of the inflammatory responses in ECM is the breakdown of the Blood Brain Barrier which is determined by the extent of Evans Blue percolation into the brain tissue. Evan’s Blue has a high affinity to bind to albumin in the serum. Under normal circumstances the BBB only selectively allows certain small molecules and gases to exchange into the brain tissue while preventing the rest. When the integrity of the BBB is compromised, albumin can freely cross
the endothelial barrier into the brain tissue and since Evan’ s blue dye binds with a high affinity to albumin it crosses into the surrounding brain tissue. From the differential staining of Evans Blue staining of brains of untreated (G2) and Combination treated mice (G3, Combination F) that had been infected with P. berghei ANKA, it was evident that treatment protected the Blood Brain Barrier integrity and thus prevented the neurological damage elicited from the development of ECM (Fig 2c). The extent of extravasation as determined by quantitation of Evans Blue from the brain tissue showed that in infected untreated (G2) brains there was significant increase in the percolation of Evans Blue compared to uninfected brains (Gl) and Combination treated (G3, Combination F) brains were similar to uninfected brain in its profile (Fig 2d).
Example 16: Quantitative Real time PCR analysis
Experimental Cerebral Malaria is characterized by an uncontrolled increase in the level of inflammation in the brain which subsequently leads to disruption of the specialized endothelial cells that help regulate the flow of substances into and out of the brain. Key factors that play a role in the process involve expression of cell adhesion molecules, chemokines and their receptors, pro- inflammatory cytokines, co-stimulatory, and co-inhibitory molecules which collectively determine the extent and magnitude of the immune responses. qPCR analysis indicated an increase in the expression of pro-inflammatory cytokines like IFN gamma (Fig 3a), MIP 1 beta (Fig 3b), IE 12 (Fig 3c) and IL 1 beta (Fig 3d) in the brain of infected untreated animals. The increase in the expression of pro-inflammatory cytokines was also accompanied with an increase in the level of expression the chemokine receptors CCR7 (Fig 3e) and CXCR3 (Fig 3f), of the chemokine CXCL10 (Fig 3g), and cell adhesion molecule ICAM 1 in brain (Fig. 3h). There was an increase in the expression of both co-inhibitory molecules PD1 (Fig 3i), PDL1 (Fig 3j), PDL2 (Fig 3k), and CTLA4 (Fig. 31) and co-stimulatory molecules CD40 (Fig 3m), CD80 (Fig 3o), CD86 (Fig. 3p) in the brain of untreated animals whereas there was no significant change in the expression levels of CD40L (Fig. 3n). Treatment of P. berghei ANKA infected mice with combination therapy F significantly decreased the expression of IFN gamma (Fig 3a), MIP 1 beta (Fig 3b), IL 12 (Fig 3c), IL 1 beta (Fig 3d), CCR7 (Fig 3e), CXCR3 (Fig 3f), CXCL10 (Fig 3g), ICAM 1 (Fig 3h), PD1 (Fig 3i), PDL1 (Fig 3j), PDL2 (Fig 3k), CTLA4 (Fig 31), CD40 (Fig 3m) , CD80 (Fig 3o), CD86 (Fig 3p), in the brain.
Example 17: Serum cytokine Analysis by ELISA
The mean levels of IFN gamma (Fig 4a), TNF alpha (Fig 4b), IL 12 (Fig 4c), IL 6 (Fig 4d), IL 4 (Fig 4e) and IL 10 (Fig 4f) in the serum of uninfected (Gl) mice were 71.5, 39.5, 91.0, 28.5, 11.5 and 79.0 pg/ml respectively. The mean levels of IFN gamma (Fig 4a), TNF alpha (Fig 4b), IL 12 (Fig 4c), IL 6 (Fig 4d), IL 4 (Fig 4e) and IL 10 (Fig 4f) in the serum of untreated (G2) mice were 1180.0, 474.5, 1118.5, 487.5, 27.0 and 260.5 pg/ml respectively. The mean levels of IFN gamma (Fig 4a), TNF alpha (Fig 4b), IL 12 (Fig 4c), IL 6 (Fig 4d), IL 4 (Fig 4e) and IL 10 (Fig 4f) in the serum of Combination treated (G3, Combination F) mice were 110.5, 41.0, 124.5, 28.5, 39.5 and 189.5 pg/ml respectively. Infection with P. berghei ANKA resulted in significant increase of the pro inflammatory cytokines IFN gamma, TNF alpha, IL 12, and IL 6 in the blood. There was also a significant increase in the anti inflammatory cytokine IL 10 however the increase in the levels of pro inflammatory cytokines were far greater than that of the anti inflammatory IL 10. Therefore, the slight increase observed in IL 10 levels of P. berghei ANKA infected untreated mice was possibly because of a measure to control the excessive inflammation. Combination treatment significantly lowered the levels of the pro inflammatory cytokines whereas it significantly increased the levels of IL 4 and IL 10 in the serum. Thus treatment with Combination lowered the extent of systemic inflammation in P. berghei ANKA infected C57BL/6 mice.
Example 18: FACS analysis of splenocytes
In the uninfected group (Gl), 23.3% of CD3+CD4+ T cells in the spleen expressed Tbet whereas the percentage of CD3+CD4+Tbet+ T cells increased to 38.6% in the infected untreated group (G2) on day 10-12 post infection (Fig. 5a). The percentage of CD3+CD4+GATA3+ T cells (Fig. 5b) in the spleen decreased to 20.8% in infected untreated group (G2) on day 10-12 post infection as compared to 30.4% in uninfected group (Gl). Therefore, Flow cytometric analysis indicated a change in the Thl/Th2 axis of infected untreated animals (G2) on day 10-12 post infection in comparison to uninfected animals (Gl) with the response in the case of infected untreated animals being more Thl skewed as evidenced by a increased expression of Tbet and lowered expression of GATA3 in CD3+CD4+ T cells isolated from the spleen (Fig. 5B). The expression of CD3+CD4+CD25+Foxp3 T cells (Fig. 5c) in the spleen of infected untreated (G2) animals on day 10-12 post infection was 5.0% in comparison to 8.9% in the uninfected animals (Gl). In contrast, the percentage of CD3+CD4+Tbet+ T cells, CD3+CD4+GATA3+ T cells and CD3+CD4+CD25+Foxp3 T cells on day 10-12 post infection in the spleen was 23.9% (Fig 5a),
29.9% (Fig 5b) and 9.8% (Fig 5c) respectively in the Combination treated group (G3, Combination F).
Claims
1. A method for preparation of pharmaceutical compound with increased water solubility comprising the steps of : a. Dissolvingthe water insoluble pharmaceutical compound in 0.5-5 L of hot distilled ethanol. b. The solution was sprayed into equal volume of MilliQ water containing 0.1 -5.0 % polysorbate 80, and kept at 60 degree C and stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM over a period of 1 hour until the dissolved material precipitates. c. Filtration of the precipitate of step (b)from the slurry d. Homogenization of the precipitate of step (c) after suspending in 1 -5 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly disperesed. e. Lyophilisation of the suspension of step (d) at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain nanoparticles of 10-500 nm range
2. The pharmaceutical compound as claimed in claim 1, dissolved in quantity of ranging between 1-50 grams.
3. The method of preparation of water soluble curcumin as claimed in claim 1, comprising the steps of: a. Dissolving 1-10 grams of curcumin (Sigma, USA) in 0.8-1 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. b. Spraying the solution of step (a) slowly over a required volume of Milli Q water containing 0.5- 3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol concentration became 50-40% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. c. Filtration of the precipitated material of step (b) from the slurry and homogenized after suspending in 1-2 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly dispersed.
d. Lyophilization of the suspension of step (c) at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain curcumin nanoparticles (CUR) of 10-500 nm range which makes the compounds soluble in water. The method of preparation of water soluble artemisininas claimed in claim 1, comprising the steps of: a. Dissolving 10-20 grams of artemisinin (Sigma, USA) in 1-2 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. b. Spraying the solution of step (a) slowly over a required volume of Milli Q water containing 1-3% polysorbate 80 over a period of 45 min to 1 hour until the ethanol concentration became 20-30% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. c. Filtration of the precipitated material of step (b) from the slurry and homogenized after suspending in 2-5 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly dispersed. d. Lyophilization of the suspension of step (c) at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain artemisinin nanoparticles (ART) of 10-500 nm range which makes the compounds soluble in water. The method of preparation of water soluble gingerolas claimed in claim 1, comprising the steps of: a. Dissolving 1-5 grams of gingerol (Sigma, USA) were dissolved in 3-5 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. b. Spraying the solution of step (a) slowly over a required volume of Milli Q water containing 1- 3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol concentration became 60-50% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. c. Filtration of the precipitated material of step (b) from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly dispersed.
d. Lyophilization of the suspension of step (c) at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain gingerol nanoparticles (GIN) of 10-500 nm range which makes the compounds soluble in water. The method of preparation of water soluble resveratrol as claimed in claim 1, comprising the steps of: a. Dissolving 20-30 grams of resveratrol (Sigma, USA) were dissolved in 1-3 L of distilled ethanol at 60 degree C and filtered to obtain a clear solution. b. Spraying the solution of step (a) slowly over a required volume of Milli Q water containing 1-3% polysorbate 80 over a period of 30 min to 45 mins until the ethanol concentration became 20-30% (V/V) while being stirred in a high-speed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM. c. Filtration of the precipitated material of step (b) from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly dispersed. d. Lyophilization of the suspension of step (c) at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain resveratrol nanoparticles (RES) of 10-500 nm range which makes the compounds soluble in water. The method of preparation of water soluble andrographolideas claimed in claim 1, comprising the steps of: a. Dissolving 1-5 grams of Andrographolide (Sigma, USA) was dissolved in 0.5-1 L of a mixture of distilled ethanol and acetone in 9: 1 - 7:3 ratio at room temperature and filtered to obtain a clear solution. b. Spraying the solution of step (a) slowly over a required volume of Milli Q water containing 2-3% polysorbate 80 over a period of 30 min to 1 hour until the ethanol: acetone concentration became 60-50% (V/V) while being stirred in a highspeed homogenizer (T 25 digital ULTRA-TURAX, IKA, USA) at 12,000-15,000 RPM.
c. Filtration of the precipitated material of step (b) from the slurry and homogenized after suspending in 0.5-1 L of MilliQ water in an ultrasonic probe sonicator at 30 KHz for 20 to 30 mins with 9 sec pulse till the material is uniformly dispersed. d. Lyophilization of the suspension of step (c) at -55 degree C in Alpha 1-2LD plus Freeze dryer to obtain curcumin nanoparticles (CUR) of 10-500 nm range which makes the compounds soluble in water. A Pharmaceutical formulation prepared using the actives from the method as claimed in claim 1, for the treatment of cerebral malaria infection comprising of 1 to 3 mg nanoartemisininin combination with 2 to 5 mg nanoallylated chalcone9. A Pharmaceutical formulation prepared using the actives from the method as claimed in claim 1, for the treatment of cerebral malaria infection comprising of 1 to 3 mg nanogingerolin combination with 0.5 to 3 mg nanoandrographolide. A pharmaceutical formulation prepared using the actives from the method as claimed in claim 1, for the treatment of cerebral malaria infection comprising ofl to 3 mg nanoresveratrolin combination with 3 to 5mg nanocurcumin. The pharmaceutical formulation as claimed in claim 8-10 preferably administered orally. The pharmaceutical formulation as claimed in claim 8-11 preferably used for the treatment of chronic inflammatory conditions like cerebral malaria, MA-ARDS, covid- 19, viral encephalitis, Inflammatory Bowel disease. A pharmaceutical formulation comprising the active as prepared from claim 1 and pharmaceutical acceptable excipients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202031028315 | 2021-01-03 | ||
IN202031028315 | 2021-01-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022144927A1 true WO2022144927A1 (en) | 2022-07-07 |
Family
ID=82261144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2021/051222 WO2022144927A1 (en) | 2021-01-03 | 2021-12-31 | A method of preparation of pure pharmaceutical compounds and pharmaceutical formulation thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022144927A1 (en) |
-
2021
- 2021-12-31 WO PCT/IN2021/051222 patent/WO2022144927A1/en active Application Filing
Non-Patent Citations (3)
Title |
---|
DENDE CHAITANYA, MEENA JAIRAM, NAGARAJAN PERUMAL, NAGARAJ VISWANATHAN ARUN, PANDA AMULYA KUMAR, PADMANABAN GOVINDARAJAN: "Nanocurcumin is superior to native curcumin in preventing degenerative changes in Experimental Cerebral Malaria", SCIENTIFIC REPORTS, vol. 7, no. 1, 1 December 2017 (2017-12-01), pages 10762, XP055955301, DOI: 10.1038/s41598-017-10672-9 * |
KARTHIKEYAN ADHIMOOLAM, KARTHIKEYAN ADHIMOOLAM, SENTHIL NATESAN, MIN TAESUN: "Nanocurcumin: A Promising Candidate for Therapeutic Applications", FRONTIERS IN PHARMACOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 11, 1 May 2020 (2020-05-01), CH , pages 487, XP055955303, ISSN: 1663-9812, DOI: 10.3389/fphar.2020.00487 * |
OYEYEMI OYETUNDE, OYEYEMI OYETUNDE, MORENKEJI OLAJUMOKE, AFOLAYAN FUNMILAYO, DAUDA KABIRU, BUSARI ZULAIKHA, MEENA JAIRAM, PANDA AM: "Curcumin-Artesunate Based Polymeric Nanoparticle; Antiplasmodial and Toxicological Evaluation in Murine Model", FRONTIERS IN PHARMACOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 9, 30 May 2018 (2018-05-30), CH , pages 562, XP055955306, ISSN: 1663-9812, DOI: 10.3389/fphar.2018.00562 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gutiérrez et al. | New approaches from nanomedicine for treating leishmaniasis | |
CA2884707C (en) | Method of treating cancer | |
Mohideen et al. | Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir | |
Jain et al. | Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation | |
JP6870053B2 (en) | Tumor-killing and antibacterial compositions and methods | |
US9149441B2 (en) | Nanospheres encapsulating bioactive material and method for formulation of nanospheres | |
Fonseca-Santos et al. | The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems | |
preet Kaur et al. | Preparation and characterization of rivastigmine loaded chitosan nanoparticles | |
Fang et al. | Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy | |
JP2013531071A (en) | Antiviral properties of Aloe vera and acquired immune deficiency syndrome (AIDS) treatment | |
Peng et al. | Targeting mast cells and basophils with anti-FcεRIα fab-conjugated celastrol-loaded micelles suppresses allergic inflammation | |
US20200253868A1 (en) | Cell autophagy inhibitor and preparation method therefor and application thereof | |
Cai et al. | The secretion of sIgA and dendritic cells activation in the intestinal of cyclophosphamide-induced immunosuppressed mice are regulated by Alhagi honey polysaccharides | |
Yang et al. | Highly effective corneal permeability of reactive oxygen species-responsive nano-formulation encapsulated cyclosporine a for dry eye management | |
Tao et al. | Oral delivery of chitosan-coated PLGA nanoemulsion loaded with artesunate alleviates ulcerative colitis in mice | |
KR101671376B1 (en) | Sustained-Release Preparations for preventing or treating porcine Salmonella typhimurium infection and PRRS Virus and Method of Preparing the Same | |
WO2016176558A1 (en) | Adjuvant particles comprising adenosine receptor antagonists | |
Lou et al. | Suppression of NLRP3/Caspase-1/GSDMD Mediated Corneal Epithelium Pyroptosis Using Melatonin-Loaded Liposomes to Inhibit Benzalkonium Chloride-Induced Dry Eye Disease | |
WO2022144927A1 (en) | A method of preparation of pure pharmaceutical compounds and pharmaceutical formulation thereof | |
Gadhave et al. | Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: Multiple sclerosis | |
Zhang et al. | Carboxymethyl chitosan nanoparticles loaded with Ctenopharyngodon idella interferon-γ2 (CiIFN-γ2) enhance protective efficacy against bacterial infection in grass carp | |
US20180064821A1 (en) | Site specific curcumin-polymer molecular complexes and methods of treating colon diseases and inflammation | |
Teng et al. | Intranasal Morphology Transformation Nanomedicines for Long-Term Intervention of Allergic Rhinitis | |
US20220395477A1 (en) | Compositions and methods for preventing and treating respiratory syncytial virus infection | |
US11471412B1 (en) | Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21914905 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21914905 Country of ref document: EP Kind code of ref document: A1 |